Please enter your username and password below, if you are not yet a member of Oncology Central remember you can register for free.
Already have an account? Login here
Categories // Subject Area // News
Researchers have discovered that a small proportion of men with end-stage prostate cancer respond to the immunotherapy Keytruda™ (pembrolizumab), with some gaining years of extra life.
It's completely free
Written ByHeather Jones, Future Science Group
Updated 29 November, 2019